Oncogenic RABL6A promotes NF1-associated MPNST progression in vivo.
Jordan L KohlmeyerCourtney A KaemmerJoshua J LingoEllen VoigtMariah R LeidingerGavin R McGivneyAmanda SchererStacia L KoppenhaferDavid J GordonPatrick J BrehenyDavid K MeyerholzMunir R TanasRebecca D DoddDawn E QuellePublished in: Neuro-oncology advances (2022)
inactivated settings. However, sustained RABL6A loss may provide selective pressure for unwanted alterations, including increased Myc, cellular atypia, and polyploidy, that ultimately promote a hyper-proliferative tumor phenotype akin to drug-resistant lesions.